DE2759793C2 - Mittel zur Verbesserung der Durchblutung und Wundheilung - Google Patents
Mittel zur Verbesserung der Durchblutung und WundheilungInfo
- Publication number
- DE2759793C2 DE2759793C2 DE2759793A DE2759793A DE2759793C2 DE 2759793 C2 DE2759793 C2 DE 2759793C2 DE 2759793 A DE2759793 A DE 2759793A DE 2759793 A DE2759793 A DE 2759793A DE 2759793 C2 DE2759793 C2 DE 2759793C2
- Authority
- DE
- Germany
- Prior art keywords
- udf53
- udf54
- udf50
- wound healing
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000017531 blood circulation Effects 0.000 title claims description 11
- 230000029663 wound healing Effects 0.000 title claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000003918 blood extract Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000271517 Bothrops jararaca Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008727 cellular glucose uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2759793A DE2759793C2 (de) | 1977-06-28 | 1977-06-28 | Mittel zur Verbesserung der Durchblutung und Wundheilung |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19772729096 DE2729096A1 (de) | 1977-06-28 | 1977-06-28 | Verwendung der inhibitorpeptide der angiotensinumwandlung als mittel zur senkung des blutzuckerspiegels |
| DE2759793A DE2759793C2 (de) | 1977-06-28 | 1977-06-28 | Mittel zur Verbesserung der Durchblutung und Wundheilung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2759793C2 true DE2759793C2 (de) | 1987-01-02 |
Family
ID=25772217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2759793A Expired DE2759793C2 (de) | 1977-06-28 | 1977-06-28 | Mittel zur Verbesserung der Durchblutung und Wundheilung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2759793C2 (nl) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947575A (en) * | 1969-06-30 | 1976-03-30 | E. R. Squibb & Sons, Inc. | Peptides as argiotensin converting enzyme inhibitors |
-
1977
- 1977-06-28 DE DE2759793A patent/DE2759793C2/de not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947575A (en) * | 1969-06-30 | 1976-03-30 | E. R. Squibb & Sons, Inc. | Peptides as argiotensin converting enzyme inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| Med. Welt, 19, 1968, 198-200 * |
| Unlisted Drugs, 24, 176, Solcoseryl, 1972 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69529932T2 (de) | Tränendrüsenspezifische Emulsionen zur topischen Anwendung an okuläre Gewebe | |
| DE2700043C2 (de) | Mittel zur Verbesserung der Durchblutung und Wundheilung | |
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69621603T2 (de) | Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln | |
| DE69636308T2 (de) | Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe | |
| DE60118859T2 (de) | Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| DE69414904T2 (de) | Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen | |
| DE69526882T2 (de) | Esculosid enthaltende Zubereitungen und ihre Verwendung in der Kosmetik und Pharmazie | |
| DE60012230T2 (de) | Verwendung einer oligosaccharide enthaltenden dermatologischen zubereitung zur behandlung von hauterkrankungen | |
| DE3511609C2 (nl) | ||
| EP0037488A2 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
| DE69834638T2 (de) | Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom | |
| DE69730214T2 (de) | Zusammensetzung und verfahren zur behandlung von herpes simplex | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| DE2206570C3 (de) | Verwendung von (+)-Catechin | |
| EP0914138B1 (de) | Komplexe zubereitungen gekennzeichnet durch einen gehalt an betain | |
| DE60036639T2 (de) | Verwendung von sumsoo-extrakt in pharmazeutischen verbindungen zur prävention und behandlung erektiler impotenz | |
| DE2658984C2 (de) | Injizierbare Insulinpräparate | |
| DE2759793C2 (de) | Mittel zur Verbesserung der Durchblutung und Wundheilung | |
| DE69531166T2 (de) | Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen | |
| EP0000124B1 (de) | Mittel zur Senkung des Blutzuckerspiegels und Verbesserung der Durchblutung und Wundheilung | |
| DE69533742T2 (de) | Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis | |
| EP0001124A1 (de) | Neue Arzneimittelmischungen zur Verbesserung der Glucoseverwertung in den Zellen und Senkung des Blutzuckerspiegels | |
| DE2518509C3 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OI | Miscellaneous see part 1 | ||
| OI | Miscellaneous see part 1 | ||
| OD | Request for examination | ||
| 8127 | New person/name/address of the applicant |
Owner name: THERA GESELLSCHAFT FUER PATENTVERWERTUNG MBH, 8130 |
|
| 8181 | Inventor (new situation) |
Free format text: ANTRAG AUF NICHTNENNUNG |
|
| AC | Divided out of |
Ref country code: DE Ref document number: 2729096 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HORMON-CHEMIE MUENCHEN GMBH, 8000 MUENCHEN, DE |
|
| 8364 | No opposition during term of opposition |